Drug Profile
Research programme: eye disorder therapeutics - AbbVie
Latest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Developer AbbVie
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2016 No recent reports of development identified for research development in Eye-disorders in USA (Ophthalmic, Injection)